Sugammadex: What do we know and what do we still need to know? A review of the recent (2013 to 2014) literature

Anaesthesia and Intensive Care

Volumn 43, Issue 1, 2015, Pages 14-22

  Ledowski, T ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Residual neuromuscular blockade; Sugammadex

Indexed keywords

NEOSTIGMINE; ROCURONIUM; SUGAMMADEX; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ANAPHYLAXIS; COMORBIDITY; DRUG INFORMATION; DRUG RESEARCH; HUMAN; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; NEUROMUSCULAR MONITORING; PARALYSIS; POSTOPERATIVE PERIOD; REVIEW; TREATMENT OUTCOME; ANESTHETIC RECOVERY; ANTAGONISTS AND INHIBITORS; AUSTRALIA; DOSE RESPONSE;

ANESTHESIA RECOVERY PERIOD; AUSTRALIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 84920446918     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1504300104     Document Type: Review

References (102)

1. Ledowski T, Hillyard S, Kozman A, Johnston F, Gillies E, Greenaway M et al. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anaesth Intensive Care 2012; 40:340-343.
2. Dubois PE, Mulier JP. A review of the interest of sugammadex for deep neuromuscular blockade management in Belgium. Acta Anaesthesiol Belg 2013; 64:49-60.
3. Beny K, Piriou V, Dussart C, Henaine R, Aulagner G, Armoiry X. [Impact of sugammadex on neuromuscular blocking agents use: a multicentric, pharmaco-epidemiologic study in French university hospitals and military hospitals]. Ann Fr Anesth Reanim 2013; 32:838-843.
4. Della RG, Di MP, Beretta L, De Gaudio AR, Ori C, Mastronardi P. Do we need to use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Position Paper on Sugammadex use. Minerva Anestesiol 2013; 79:661-666.
5. Chon JY. In the hour of Sugammadex. Korean J Anesthesiol 2013; 64:3-5.
6. Doi Y, Kagawa T. [Update on the practical use of new anesthetic agents]. Masui 2013; 62:1088-1096.
7. Epemolu O, Bom A. The concept behind sugammadex. Rev Esp Anestesiol Reanim 2014; 61:272-276.
8. Karalapillai D, Kaufman M, Weinberg L. Sugammadex. Crit Care Resusc 2013; 15:57-62.
9. Kirienko PA, Babaiants AV, Shmakov IA, Gorobets ES, El'dzharkiev AA, Gel'fand BR. [Assessment of sugammadex use efficiency and safety for neuromuscular block reversion]. Anesteziol Reanimatol 2013; n/a:46-51.
10. Lee S. Sugammadex: a turning point in our practice. Korean J Anesthesiol 2013; 65:493-494.
11. Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid 2013; 8:57-67.
12. Sokol-Kobielska E. Sugammadex-indications and clinical use. Anaesthesiol Intensive Ther 2013; 45:106-110.
13. Welliver MD. New and advanced options in neuromuscular blockade management. AANA J 2013; Suppl:12-17.
14. Della Rocca G, Pompei L, Pagan DE, Paganis C, Tesoro S, Mendola C et al. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study. Acta Anaesthesiol Scand 2013; 57:1138-1145.
15. Woo T, Kim KS, Shim YH, Kim MK, Yoon SM, Lim YJ et al. Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients. Korean J Anesthesiol 2013; 65:501-507.
16. Ledowski T, Hillyard S, O'Dea B, Archer R, Vilas-Boas F, Kyle B. Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome. Indian J Anaesth 2013; 57:46-51.
17. von Quillfeldt S, Fohre B, Andrees N, Spies CD, Galvagni D, Joussen AM et al. Rocuronium reversed by sugammadex versus mivacurium during high-risk eye surgery: an institutional anaesthetic practice evaluation. J Int Med Res 2013; 41:1740-1751.
18. Ledowski T, Falke L, Johnston F, Gillies E, Greenaway M, De Mel A et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. Eur J Anaesthesiol 2014; 31:423-429.
19. Llaurado S, Sabate A, Ferreres E, Camprubi I, Cabrera A. Postoperative respiratory outcomes in laparoscopic bariatric surgery: Comparison of a prospective group of patients whose neuromuscular blockade was reverted with sugammadex and a historical one reverted with neostigmine. Rev Esp Anestesiol Reanim 2014; n/a:n/a.
20. Castro DS Jr, Leao P, Borges S, Gomes L, Pacheco M, Figueiredo P. Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surg Laparosc Endosc Percutan Tech 2014; 24:420-423.
21. Esteves LO. Case of anaphylaxis induced by rocuronium treated with sugammadex. Braz J Anesthesiol 2013; 63:511.
22. Ishikawa T, Kawanoue N, Minami E, Iwasaki E, Ishii M, Kobayashi H et al. [A case of rocuronium-induced anaphylactic shock successfully treated with sugammadex]. Masui 2013; 62:1230-1232.
23. Conte B, Zoric L, Bonada G, Debaene B, Ripart J. Reversal of a rocuronium-induced grade IV anaphylaxis via early injection of a large dose of sugammadex. Can J Anaesth 2014; 61:558-562.
24. Raft J, Belhadj-Tahar N, Meistelman C. Slow recovery after sugammadex bolus after rocuronium-induced anaphylaxis. Br J Anaesth 2014; 112:1115-1116.
25. Kalkan Y, Tumkaya L, Bostan H, Tomak Y, Altuner D, Yilmaz A et al. Effect of sugammadex on rocuronium induced changes in pancreatic mast cells. Toxicol Ind Health 2013; n/a:n/a.
26. Benham SW. Sugammadex in anticipated difficult airways(3.). Anaesthesia 2013; 68:1190-1191.
27. Copp MV. Sugammadex in anticipated difficult airways(5.). Anaesthesia 2013; 68:1192.
28. Dalton AJ, McGuire B, Rodney G. Sugammadex in anticipated difficult airways(4.). Anaesthesia 2013; 68:1191-1192.
29. Elliott SK, Ball DR. Sugammadex in anticipated difficult airways(2.). Anaesthesia 2013; 68:1190.
30. Gutierrez GR, Abad GA, Cubek QD, Jimenez SC. [Can sugammadex save the situation of a "no intubation, no ventilation" patient?]. Rev Esp Anestesiol Reanim 2013; 60:411-412.
31. Kuroiwa K, Mochizuki T, Sato S. [A case of an unexpected difficult nasal intubation, caused by hypertrophied lingual tonsil]. Masui 2013; 62:172-174.
32. Mendonca C. Sugammadex to rescue a 'can't ventilate' scenario in an anticipated difficult intubation: is it the answer? Anaesthesia 2013; 68:795-759.
33. Montealegre-Angarita MC, Llaurado-Paco S, Sabate A, Ferreres E, Cabrera A, Camprubi I. [Analysis of difficult intubation factors in bariatric surgery. Influence of the choice of neuromuscular blocker on the availability of sugammadex]. Rev Esp Anestesiol Reanim 2013; 60:434-439.
34. Paton L, Gupta S, Blacoe D. Successful use of sugammadex in a 'can't ventilate' scenario. Anaesthesia 2013; 68:861-864.
35. Turnbull J, Suaris P. Sugammadex in anticipated difficult airways(1.). Anaesthesia 2013; 68:1189-1190.
36. Luxen J, Trentzsch H, Urban B. [Rocuronium and sugammadex in emergency medicine: requirements of a muscle relaxant for rapid sequence induction]. Anaesthesist 2014; 63:331-337.
37. Woloszczuk-Gebicka B, Zawadzka-Glos L, Lenarczyk J, Sitkowska BD, Rzewnicka I. Two cases of the "cannot ventilate, cannot intubate" scenario in children in view of recent recommendations. Anaesthesiol Intensive Ther 2014; 46:88-91.
38. Ozbilgin S, Ozbilgin M, Kucukoztas B, Kamaci G, Unek T, Yurtlu BS et al. Evaluation of the effectiveness of sugammadex for verapamil intoxication. Basic Clin Pharmacol Toxicol 2013; 113:280-285.
39. Aceto P, Perilli V, Modesti C, Ciocchetti P, Vitale F, Sollazzi L. Airway management in obese patients. Surg Obes Relat Dis 2013; 9:809-815.
40. Carron M, Ieppariello G, Ori C. Sugammadex in a patient with Sjogren's syndrome and polymyositis. Br J Anaesth 2013; 111:1034-1035.
41. Carron M, Veronese S, Foletto M, Ori C. Sugammadex allows fast-track bariatric surgery. Obes Surg 2013; 23:1558-1563.
42. Conde R, Pereira M. Anesthetic management of a patient with Brugada syndrome-the use of sugammadex in major abdominal surgery. Rev Bras Anestesiol 2013; 63:159-160.
43. Franco-Hernandez JA, Rodriguez LM, Ortiz de Landazuri PJ, Hernandez AG. Use of sugammadex in Strumpell-Lorrain disease: a report of two cases. Rev Bras Anestesiol 2013; 63:113-115.
44. Gonzalez A, Benavides J, Lema G. Anesthesia and electroconvulsive therapy: when succinylcholine is contraindicated. J ECT 2013; 29:75-76.
45. Grandjean B, Guerci P, Vial F, Raft J, Fuchs-Buder T, Bouaziz H. [Sugammadex and profound rocuronium neuromuscular blockade induced by magnesium sulphate]. Ann Fr Anesth Reanim 2013; 32:378-379.
46. Hamada K, Kayashima K. [Management of cesarean section under general anesthesia using sugammadex]. Masui 2013; 62:75-77.
47. Inamori M, Imashuku Y, Sonobe S, Sukenaga C, Yabuta K, Hashimura T et al. [General anesthetic management of a patient with spinal muscular atrophy type III]. Masui 2013; 62:702-704.
48. Kadoi Y, Nishida A, Saito S. Recovery time after sugammadex reversal of rocuronium-induced muscle relaxation for electroconvulsive therapy is independent of cardiac output in both young and elderly patients. J ECT 2013; 29:33-36.
49. Kelsaka E, Karakaya D, Zengin EC. Use of sugammadex in a patient with amyotrophic lateral sclerosis. Med Princ Pract 2013; 22:304-306.
50. Kiss G, Lacour A, d'Hollander A. Fade of train-of-four ratio despite administration of more than 12 mg kg(-1) sugammadex in a myasthenia gravis patient receiving rocuronium. Br J Anaesth 2013; 110:854-855.
51. Langley A, Davie M. Sugammadex and general anaesthesia in a patient with Brugada syndrome. Anaesth Intensive Care 2013; 41:434.
52. Lobaz S, Sammut M, Damodaran A. Sugammadex rescue following prolonged rocuronium neuromuscular blockade with 'recurarisation' in a patient with severe renal failure. BMJ Case Rep 2013; 2013:doi: 10.11.36|ber-2012-007603.
53. Matinyan NV, Saltanov AI, Mareeva AA. [Sugammadex use experience in pediatric oncology]. Anesteziol Reanimatol 2013; n/a:34-37.
54. Nakamori E, Nitahara K, Sugi Y, Katori K, Matsuzaki A, Higa K. [Reversal of rocuronium induced neuromuscular block with sugammadex in a patient with myasthenia gravis]. Masui 2013; 62:972-974.
55. Neimark MI, Bulganin AA. [Controlled myorelaxation in patients with aldosteroma]. Anesteziol Reanimatol 2013; n/a:14-18.
56. Nonaka T, Fujimoto M, Nishi M, Yamamoto T. [The effect of rocuronium and sugammadex in hepatic tumor patients without preoperative hepatic impairment]. Masui 2013; 62:304-308.
57. Ota C, Ueta K, Imada T, Hayashi Y, Mashimo T. [Sugammadex reversal after extubation under muscle relaxation to prevent cough reflex in a patient with intractable spontaneous pneumothorax]. Masui 2013; 62:968-971.
58. Pickard A, Lobo C, Stoddart PA. The effect of rocuronium and sugammadex on neuromuscular blockade in a child with congenital myotonic dystrophy type 1. Pediatr Anesth 2013; 23:871-873.
59. Sanfilippo M, Wefki Abdelgawwad Shousha AA, Paparazzo A. Emergence in elderly patient undergoing general anesthesia with xenon. Case Rep Anesthesiol 2013; 2013:736790.
60. Stewart PA, Phillips S, De Boer HD. Sugammadex reversal of rocuronium-induced neuromuscular blockade in two types of neuromuscular disorders: Myotonic dystrophy and spinal muscular atrophy. Rev Esp Anestesiol Reanim 2013; 60:226-229.
61. Stourac P, Krikava I, Seidlova J, Strazevska E, Huser M, Hruban L et al. Sugammadex in a parturient with myotonic dystrophy. Br J Anaesth 2013; 110:657-658.
62. Sungur Ulke Z, Yavru A, Camci E, Ozkan B, Toker A, Senturk M. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiol Scand 2013; 57:745-748.
63. Yuksel E, Sergin D, Tanatti B, Alper I. Rocuronium-sugammadex use in electroconvulsive therapy of patients with pseudocholinesterase enzyme deficiency. J Clin Anesth 2013; 25:680-681.
64. Buijs EJ, Scholten JGF, Ros JJW. Successful administration of sugammadex in a patient with acute porphyria: A case report. Eur J Anaesthesiol 2014; 31:439-441.
65. Carron M, Gasparetto M, Vindigni V, Foletto M. Laparoscopic surgery in a morbidly obese, high-risk cardiac patient: the benefits of deep neuromuscular block and sugammadex. Br J Anaesth 2014; 113:186-187.
66. Chang YJ, Jung WS, Son WR, Jo YY. Discordance between train-of-four response and clinical symptoms in a patient with amyotrophic lateral sclerosis. Acta Med Okayama 2014; 68:125-127.
67. Czarnetzki C, Tassonyi E, Lysakowski C, Elia N, Tramer MR. Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium: a randomized controlled trial. Anesthesiology 2014; 121:59-67.
68. Kayashima K, Noda Y, Hayashi T, Yoshino H. [Case of delayed extubation in a woman with low pulmonary function]. Masui 2014; 63:153-156.
69. Matsuda K, Yakushiji T, Ryo J, Higashimoto S, Sasaki K. [Anesthetic management of a patient with 8 trisomy mosaic combined with cerebral palsy]. Masui 2014; 63:459-461.
70. Sakurai Y, Uchida M, Aiba J, Mimura F, Yamaguchi M, Kakumoto M. [Reversal of rocuronium-induced neuromuscular blockade with sugammadex in patients for cesarean delivery treated with magnesium sulfate]. Masui 2014; 63:315-319.
71. Salas BA, de Carlos VJC, Clavero RC, Miralles MF. [Extubation failure due to prolonged residual block after vecuronium. Treatment with sugammadex]. An Pediatr (Barc) 2014; 80:e92-e93.
72. Saricicek V, Sahin L, Bulbul F, Ucar S, Sahin M. Does rocuroniumsugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression? J ECT 2014; 30:30-34.
73. Wefki Abdelgawwad Shousha AA, Sanfilippo M, Sabba A, Pinchera P. Sugammadex and reversal of neuromuscular block in adult patient with duchenne muscular dystrophy. Case Rep Anesthesiol 2014; 2014:680568.
74. Staals LM, Snoeck MMJ, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW et al. Reduced clearance of rocuronium and sugammadex in patients with severe to endstage renal failure: a pharmacokinetic study. Br J Anaesth 2010; 104:31-39.
75. Shimizu T, Toda Y, Shimizu K, Iwasaki T, Kanazawa T, Ishii N et al. [Increase in serum vecuronium concentration following sugammadex administration in a pediatric patient after prolonged sedation]. Masui 2013; 62:1225-1229.
76. Cammu G, Van Vlem B, van den Heuvel M, Stet L, el Galta R, Eloot S et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth 2012; 109:382-390.
77. Fabregat Lopez J, Porta Vila G, Martin-Flores M. Reversal of moderate and intense neuromuscular block induced by rocuronium with low doses of sugammadex for intraoperative facial nerve monitoring. Rev Esp Anestesiol Reanim 2013; 60:465-468.
78. Kopman AF, Brull SJ. Low-dose sugammadex reversal: there is no such thing as a free lunch. Anesthesiology 2013; 119:10-12.
79. Pongracz A, Szatmari S, Nemes R, Fulesdi B, Tassonyi E. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. Anesthesiology 2013; 119:36-42.
80. Sanfilippo M, Alessandri F, Wefki Abdelgawwad Shousha AA, Sabba A, Cutolo A. Sugammadex and ideal body weight in bariatric surgery. Anesthesiol Res Pract 2013; 2013:389782.
81. Schmartz D, Guerci P, Fuchs-Buder T. Sugammadex dosing in bariatric patients. Anesthesiology 2013; 118:754.
82. Van Gestel L, Cammu G. Is the effect of sugammadex always rapid in onset? Acta Anaesthesiol Belg 2013; 64:41-47.
83. Kayashima K, Sozen R, Okura D. [Insufficient sugammadex effect in an obese pregnant woman undergoing cesarean section under general anesthesia]. Masui 2014; 63:188-190.
84. Kopman AF. Recovery times after sugammadex: is the data flawed? Acta Anaesthesiol Scand 2014; 58:496-497.
85. Van Lancker P, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia 2011; 66:721-715.
86. Carron M. Sugammadex and ideal body weight in bariatric surgery: the debate continues. Anesthesiol Res Pract 2014; 2014:762432.
87. Kotake Y, Ochiai R, Suzuki T, Ogawa S, Takagi S, Ozaki M et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013; 117:345-351.
88. Jeyadoss J, Kuruppu P, Nanjappa N, Van Wijk R. Sugammadex hypersensitivity-a case of anaphylaxis. Anaesth Intensive Care 2014; 42:89-92.
89. Sadleir PHM, Russell T, Clarke RC, Maycock E, Platt PR. Intraoperative anaphylaxis to sugammadex and a protocol for intradermal skin testing. Anaesth Intensive Care 2014; 42:93-96.
90. Savic L, Savic S, Hopkins PM. Anaphylaxis to sugammadex. Anaesth Intensive Care 2014; 42:7-9.
91. Tokuwaka J, Takahashi S, Tanaka M. Anaphylaxis after sugammadex administration. Can J Anesth 2013; 60:733-734.
92. Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia 2014; 69:1251-1257.
93. Carron M. Effects of sugammadex on coagulation: it does not represent a bleeding risk in surgical patients. Int J Clin Pharmacol Ther 2014; 52:824.
94. de Kam PJ, El Galta R, Kruithof AC, Fennema H, van Lierop MJ, Mihara K et al. No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters. Int J Clin Pharmacol Ther 2013; 51:976-985.
95. De Kam PJ, Grobara P, Prohn M, Hoppener F, Kluft C, Burggraaf J et al. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. Int J Clin Pharmacol Ther 2014; 52:227-236.
96. De Kam PJ, Kruithof AC, van Lierop MJ, Moerland M, Dennie J, Troyer MD et al. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects. Int J Clin Pharmacol Ther 2014; 52:631-641.
97. Rezonja K, Lorenzon P, Mars T. Opposing effects of dexamethasone, agrin and sugammadex on functional innervation and constitutive secretion of IL-6 in in vitro innervated primary human muscle cells. Neurosci Lett 2013; 549:186-190.
98. Rezonja K, Sostaric M, Vidmar G, Mars T. Dexamethasone produces dose-dependent inhibition of sugammadex reversal in in vitro innervated primary human muscle cells. Anesth Analg 2014; 118:755-763.
99. Staikou C, Stamelos M, Stavroulakis E. Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity. Br J Anaesth 2014; 112:217-230.
100. Suzuki M, Inagi T, Kikutani T, Mishima T, Bito H. Negative pressure pulmonary edema after reversing rocuronium-induced neuromuscular blockade by sugammadex. Case Rep Anesthesiol 2014; 2014:135032.
101. Palanca JM, Aguirre-Rueda D, Granell MV, Aldasoro M, Garcia A, Iradi A et al. Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. Int J Med Sci 2013; 10:1278-1285.
102. Hanci V, Vural A, Hanci SY, Ali KH, Omur D, Unver A. In vitro evaluation of antimicrobial features of sugammadex. Braz J Anesthesiol 2014; 64:105-108.